Evidence map›Paper›PMID 36461789›Full record

ArticleMolecular genetics & genomic medicine2023

Further characterization of the 9q31 microdeletion phenotype; delineation of a common region of overlap containing ZNF462.

Lauren Brady, Mark Ballantyne, John Duck, Thomas Fisker, Ryan Kleefman, Chumei Li, Landry Nfonsam, Lee-Anne Schultz, Mark Tarnopolsky, Elizabeth McCready

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Novel variants inTranslational pediatrics · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lauren BradyHamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Mark BallantyneHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.
John DuckHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Thomas FiskerHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Ryan KleefmanHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Chumei LiHamilton Health Sciences Centre, Hamilton, Ontario, Canada.ORCID 0000-0002-4207-6914
Landry NfonsamHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Lee-Anne SchultzHamilton Health Sciences Centre, Hamilton, Ontario, Canada.
Mark TarnopolskyHamilton Health Sciences Centre, Hamilton, Ontario, Canada.ORCID 0000-0003-0312-3746
Elizabeth McCreadyHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.ORCID 0000-0002-7952-2279
Health Sciences Centre · CA

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundLoss of function variants and whole gene deletions of ZNF462 has been associated with a novel phenotype of developmental delay/intellectual disability and distinctive facial features. Over two dozen cases have been reported to date and the condition is now known as Weiss-Kruszka syndrome (OMIM# 618619). There are several older reports in the literature and DECIPER detailing individuals with interstitial deletions of 9q31 involving the ZNF462 gene. Many of the characteristic facial features described in these microdeletion cases are similar to those who have been diagnosed with Weiss-Kruszka syndrome.

methodsWe describe three additional patients with overlapping 9q31 deletions and compare the phenotypes of the microdeletion cases reported in the literature to Weiss-Kruszka syndrome.

resultsPhenotypic overlap was observed between patients with 9q31 deletions and Weiss-Kruszka syndrome. Several additional features were noted in 9q31 deletion patients, including hearing loss, small head circumference, palate abnormalities and short stature.

conclusionsThe common region of overlap of microdeletion cases implicates ZNF462 as the main driver of the recognizable 9q31 microdeletion phenotype. The observation of additional features in patients with 9q31 microdeletions that are not reported in Weiss-Kruszka syndrome further suggests that other genes from the 9q31 region likely act synergistically with ZNF462 to affect phenotypic expression.

Indexed as

Abnormalities, MultipleChromosome DeletionChromosome StructuresDNA-Binding ProteinsHumansNerve Tissue ProteinsPhenotypeSyndromeTranscription FactorsDNA-Binding ProteinsNerve Tissue ProteinsTranscription FactorsZNF462 protein, human9q31 microdeletion syndromeWeiss-KruszkaZNF462

Identifiers

PMID36461789
PMCPMC10009906
OpenAlexW4310644815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.